Klox Technologies, which is developing a light-reactive topical gel for acne and skin care, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
September 2014 IPO Foamix Pharmaceuticals (FOMX), which is developing foam treatments for acne, priced 45% below its midpoint, but is up 50% from that offer price.
The Quebec, Canada-based company, which was founded in 2007 and booked $1.5 million in licensing fees for the 12 months ended September 30, 2014, plans to list on the NASDAQ under the symbol KLOX. Klox Technologies initially filed confidentially on December 3, 2014. UBS Investment Bank is the sole bookrunner on the deal. No pricing terms were disclosed.
